The primary motivation for studying low-dose tamoxifen is not just reducing side effects, but overcoming a massive adoption barrier where less than 5% of eligible women accept standard chemo prevention due to fear and perceived toxicity. The goal is to create a more acceptable option.
While low-dose tamoxifen cuts breast cancer risk by 50% in postmenopausal women, its benefit in premenopausal women is nuanced. It doesn't reduce overall risk but does work for the contralateral (opposite) breast, suggesting it acts as a pure preventative agent rather than treating residual disease.
A key weakness of this analysis—not comparing low-dose to full-dose tamoxifen—is actually a feature of its design. The trials enrolled women who had already refused standard prevention. The relevant clinical question for this population is 'is low-dose better than nothing?', not whether it's equivalent to a therapy they won't take.
A significant real-world hurdle for implementing low-dose tamoxifen therapy is pharmaceutical. Since it only comes in 10mg tablets, clinicians must advise patients to either cut pills in half (a physical challenge) or take a pill every other day (a memory challenge), complicating adherence for this preventative therapy.